GRAND PHARMA's strategic partner in the nuclear medicine field, Australian company Telix, has announced significant positive news. The first part of the international multi-center Phase III clinical trial for TLX591-Tx, a first-in-class lutetium-labeled therapeutic radio-antibody drug conjugate for treating prostate cancer, has successfully met its primary objectives. This initial phase focused on safety and dosimetry, confirming the product's safety and tolerability with no new adverse reactions observed. The successful outcome supports the future development and potential market approval of this innovative product, indicating a promising new treatment option for prostate cancer may be on the horizon.
As a first-in-class therapeutic rADC, TLX591-Tx possesses targeting and pharmacological properties that are significantly different from existing marketed small peptide molecules targeting Prostate-Specific Membrane Antigen. It is designed to achieve high internalization rates, long retention times, and high selectivity for PSMA. The progressing ProstACT Global trial is a randomized, open-label, international multi-center Phase III study evaluating TLX591-Tx in combination with standard therapies versus standard therapies alone for patients with PSMA-positive metastatic castration-resistant prostate cancer.
The ProstACT Global trial consists of two parts. The first part, the safety and dosimetry lead-in phase, has completed enrollment of all 36 patients. The second part is a global expansion study with a 2:1 randomization plan, aiming to enroll approximately 490 patients. Patients enrolled must be diagnosed with mCRPC via 68Ga-PSMA-11 PET imaging and have previously received one androgen receptor pathway inhibitor treatment.
Data from this first part of the Phase III trial will be submitted to the U.S. FDA to advance the second part of the study in the United States. Patient recruitment for the second part will also proceed in regions where clinical trials are approved, including mainland China.
Key results from the first part confirmed the favorable safety and tolerability profile of TLX591-Tx. Hematological events observed were transient and manageable, and dosimetry data confirmed tumor uptake. Furthermore, compared to other PSMA-targeted small molecule radioactive ligand therapies, TLX591-Tx demonstrated distinct targeting and pharmacological characteristics. Long-term follow-up of treated patients showed no significant acute or delayed kidney toxicity. Due to its larger molecular size, TLX591-Tx also exhibited very low uptake in salivary and lacrimal glands, potentially reducing side effects like dry mouth and dry eyes.
Prostate cancer is a common cancer among men, with incidence and mortality rates rising due to factors like an aging population. Market forecasts suggest significant growth potential for prostate cancer treatments, highlighting the importance of innovative therapies like those being developed by GRAND PHARMA and its partner.
Comments